Key Record Dates
| ClinicalTrials.gov Identifier: | NCT06170788 |
|---|---|
| Brief Title: | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) |
| First Submitted : | December 3, 2023 |
| First Submitted that Met QC Criteria : | December 6, 2023 |
| First Posted : | December 14, 2023 |
| Last Update Submitted that Met QC Criteria : | May 9, 2024 |
| Last Update Posted : | May 10, 2024 (Estimate) |